Hemorrhage

The grounding supports chemically induced hemorrhage, particularly bleeding associated with antithrombotic drugs such as aspirin, clopidogrel, prasugrel, dalteparin, rivaroxaban, ticagrelor, apixaban, and edoxaban. It also supports iatrogenic blood loss and bleeding in the perioperative setting.

Hemorrhage reflects loss of blood from the vascular compartment through vessel disruption or impaired hemostasis. The supplied abstracts link bleeding risk to antithrombotic therapy, altered pharmacokinetics and pharmacodynamics in extremes of body weight, and perioperative blood loss, but do not provide a more detailed biological mechanism.

Use of antithrombotic drugs is a supported risk factor, including antiplatelet agents and anticoagulants. Extremes of body weight, especially underweight and moderate-to-morbid obesity, are also associated with challenges in antithrombotic therapy and bleeding risk. Surgical procedures and perioperative settings increase bleeding risk.

The grounding supports prevention and control of bleeding rather than a specific treatment for hemorrhage itself. Relevant management approaches include patient blood management, with preoperative hemoglobin optimization, minimizing iatrogenic blood loss and bleeding, and improving tolerance to anemia. In patients with atrial fibrillation or other indications for antithrombotic therapy, guideline discussions emphasize use of non-vitamin K antagonist oral anticoagulants and holistic pathway-based care to balance thrombotic and bleeding risks.